Volume 8, Number 1Reviews in UrologySpontaneous Retroperitoneal Hemorrhage Caused by Segmental Arterial MediolysisCase ReviewHerbert LeporCourtney K PhillipsRetroperitoneal hemorrhageSegmental arterial mediolysisCase report
Volume 9, Number 2Reviews in UrologyAngiomyolipoma of the Left Ureterovesical JunctionCase ReviewElias S HyamsJohn ProvetAngiomyolipoma (AML) is a benign tumor that typically consists of 3 tissue elements: thick-walled blood vessels, smooth muscle cells, and adipocytes. The most common location for AML is renal; however, extrarenal AML has been described. Reports of extrarenal AML within the genitourinary tract are rare. We report a case of AML at the left ureterovesical junction and the evaluation and management decisions regarding this lesion. [Rev Urol. 2007;9(2):84-88]AngiomyolipomaImmunohistochemical stainingUreterovesical junction
Volume 9, Number 1Reviews in UrologySolitary Fibrous Tumor of the Kidney: A Case Report and Review of the LiteratureCase ReviewImane KamaouiAfaf AmartiSanae BennisLaila ChbaniHinde El FatemiTaoufik HarmouchFadl TaziKaoutar ZnatiA solitary fibrous tumor (SFT) is an unusual spindle cell neoplasm that usually occurs in the pleura but has recently been described in diverse extrapleural sites. Urogenital localization is rare, and only 19 cases of SFT of the kidney have been described. We report a case of a large SFT clinically thought to be renal cell carcinoma arising in the kidney of a 70-year-old man. The tumor was well circumscribed and composed of a mixture of spindle cells and dense collagenous bands, with areas of necrosis or cystic changes noted macroscopically and microscopically. Immunohistochemical studies revealed reactivity for CD34, CD99, and Bcl-2 protein, with no staining for keratin, S-100 protein, or muscle markers, confirming the diagnosis of SFT. This tumor is benign in up to 90% of cases. The immunohistochemical study is the key to diagnosis. [Rev Urol. 2007;9(1):36-40]KidneyImmunohistochemical studyRenal neoplasmSpindle cells
Volume 11, Supplement 1Reviews in UrologyPathophysiology of Benign Prostatic Hyperplasia: Insights From Medical Therapy for the DiseaseAdvances in the Pharmacologic Treatment of BPHHerbert LeporThe medical treatment of benign prostatic hyperplasia (BPH) has its roots in the early 1970s. During this era, the first clinical trials investigating α-blockade and androgen deprivation therapy were reported for men with clinical BPH. The observation that clinical BPH was improved following administration of both α-blockers and androgen deprivation therapy supported the evolving paradigm that clinical BPH resulted from dynamic and static pathways. During the past several decades, the evolution of α-blockers for the treatment of BPH has been impacted by innovations targeted to simplify the administration and improve tolerability while maintaining their effectiveness.[Rev Urol. 2009;11(suppl 1):S9–S13 doi: 10.3909/riu11S1S0002]© 2009 MedReviews®, LLCBladder outletobstructionSelectivityAdrenergic Receptors
Volume 21, Number 2Reviews in UrologyMassive Intra-abdominal Germ Cell Tumors: A Case Series and Review of LiteratureNirmish SinglaAditya BagrodiaDaniel G WongIntra-abdominal testes are at increased risk of malignant transformation and can manifest as large abdominal masses with a wide variation in presenting symptoms. In the setting of cryptorchid or nonpalpable testes, large abdominal masses are highly suspect for germ cell tumors. Without standard guidelines, management can vary extensively. Surgical management may not be trivial and can entail a major abdominal operation in the context of a multimodal approach. The use of biopsy and serum tumor markers may effectively guide sequence of management based upon expected histology. In advanced cases, neoadjuvant chemotherapy may be pursued, and retroperitoneal lymph node dissection may be accomplished at the time of orchiectomy to minimize morbidity. The development of these massive late stage tumors reaffirms current guidelines on the early correction of cryptorchidism. [Rev Urol. 2019;21(2/3):136–140] © 2019 MedReviews®, LLCTesticularSeminomaNonseminomatous